Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched its advanced proteomics capabilities powered by Olink™ Explore HT, marking a significant step in expanding large-scale multi-omics research across South Asia.

The next-generation proteomics platform enables simultaneous analysis of thousands of proteins from a single sample, paving the way for deeper insights into disease biology, biomarker discovery, translational research, and precision medicine.

As part of this milestone, Strand has successfully completed a proteomics project for a biopharma partner involving patients with chronic kidney disease, demonstrating the platform’s potential in clinical studies and translational research applications.

Olink™ Explore HT enables the measurement of more than 5,400 protein biomarkers from just 2 µL of sample, allowing Strand to deliver integrated proteomics, genomics, and clinical insights for advanced drug discovery and biomedical research programs.

Dr. Ramesh Hariharan, CEO of Strand Life Sciences, said, “With Olink™ Explore HT, Strand is bringing one of the world’s most advanced proteomics platforms to India and the region. By combining this with established strengths in genomics, bioinformatics, and clinical partnerships, Strand aims to deliver end-to-end multi-omics programs and enable faster, more impactful discovery. We welcome collaborations with global pharma and biotech partners to accelerate research and development pipelines.”